


### *Amendments to the Claims*

The listing of claims will replace all prior versions and listings of claims in the application.

1. (currently amended) A compound of formula I:



wherein,

R<sub>1</sub> is methyl, hydroxymethyl, or an ester of said hydroxymethyl;

R<sub>3</sub> and R<sub>4</sub> are independently hydrogen, halo, haloalkyl, C<sub>1-10</sub> alkyl, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, amino, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, methylenedioxy, carbonylamido or alkylthiol;

R<sub>5</sub> is hydrogen or C<sub>1-10</sub> alkyl;

A is an optionally substituted phenyl or pyridyl, wherein said optional substituent is one or more of hydrogen, halo, haloalkyl, C<sub>1-10</sub> alkyl, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, amino, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, methylenedioxy, ethylenedioxy, carbonylamido or alkylthiol;

D together with the rings to which it is fused is 4*H*-pyrrolo[2,3-*h*]chromene;

Y is ~~CN, COR<sub>19</sub>, CO<sub>2</sub>R<sub>19</sub> or CONR<sub>20</sub>R<sub>21</sub>, wherein R<sub>19</sub>, R<sub>20</sub> and R<sub>21</sub> are independently hydrogen, C<sub>1-10</sub> alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl or aminoalkyl;~~ and

Z is  $\text{NR}_{22}\text{R}_{23}$ ,  $\text{NHCOR}_{22}\text{N}(\text{COR}_{23})_2$ ,  $\text{N}(\text{COR}_{22})(\text{COR}_{23})$ ,  $\text{N=CHOR}_{19}$  or  $\text{N=CHR}_{19}$  wherein  $\text{R}_{22}$  and  $\text{R}_{23}$  are independently H or  $\text{C}_{1-4}$  alkyl;  
or a pharmaceutically acceptable salt thereof.

2. (cancelled).

3. (cancelled).

4. (original) The compound of claim 1, wherein each of  $\text{R}_3$ - $\text{R}_5$  is hydrogen.

5. (cancelled).

6. (cancelled).

7. (currently amended) The compound of claim 6 1, wherein Z is  $\text{NH}_2$ .

8.-21. (cancelled).

22. (previously presented) The compound of claim 1, wherein:

$\text{R}_1$  is methyl, hydroxymethyl or an ester of said hydroxymethyl;

$\text{R}_3$  and  $\text{R}_4$  are independently hydrogen or methyl;

A is an optionally substituted phenyl, wherein said optional substituents are independently selected from the group consisting of hydrogen, hydroxy, halogen, cyano, alkoxy and acetoxy or combines with another of the optional substituents to form methylenedioxy or ethylenedioxy;

Y is cyano; and

Z is  $\text{NR}_{22}\text{R}_{23}$ , wherein  $\text{R}_{22}$  and  $\text{R}_{23}$  are independently H or  $\text{C}_{1-4}$  alkyl.

23. (previously presented) The compound of claim 22, wherein said compound is selected from the group consisting of:

2-Amino-4-(3-bromo-4,5-dimethoxyphenyl)-3-cyano-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-4-(3-bromo-4,5-dimethoxyphenyl)-3-cyano-7-hydroxymethyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-4-(3-bromo-4-hydroxy-5-methoxyphenyl)-3-cyano-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-4-(4-acetoxy-3-bromo-5-methoxyphenyl)-3-cyano-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3,4,5-trimethoxyphenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3-nitrophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3,5-dimethoxyphenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3,4-methylenedioxy-5-methoxyphenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3-methoxyphenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3-bromophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3,5-difluorophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(4,5-dimethoxy-3-iodophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3-cyanophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3,4,5-trimethoxyphenyl)-7-hydroxymethyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3,5-dimethoxyphenyl)-7-hydroxymethyl-4*H*-pyrrolo[2,3-*h*]chromene;

4,7,10,13,16,19-Docosahexaenoic acid {2-Amino-4-(3-bromo-4,5-dimethoxyphenyl)-3-cyano-4*H*-pyrrolo[2,3-*h*]chromene}-7-ylmethyl ester;

2-Amino-3-cyano-4-(3-fluorophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(4-cyanophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3-chlorophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3,5-dichlorophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3,4-dichlorophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;  
2-Amino-3-cyano-4-(3,4-difluorophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;  
2-Amino-3-cyano-4-(3-fluoro-4-chlorophenyl)-7-methyl-4*H*-  
pyrrolo[2,3-*h*]chromene;  
2-Amino-3-cyano-4-(3-bromo-4-fluorophenyl)-7-methyl-4*H*-  
pyrrolo[2,3-*h*]chromene; and  
2-Amino-3-cyano-4-(3-cyano-4-fluorophenyl)-7-methyl-4*H*-  
pyrrolo[2,3-*h*]chromene;  
or a pharmaceutically acceptable salt thereof.

24. (cancelled).

25. (previously presented) The compound of claim 1, wherein:

R<sub>1</sub> is methyl, hydroxymethyl or an ester of said hydroxymethyl;

R<sub>3</sub> and R<sub>4</sub> are independently hydrogen or methyl;

A is an optionally substituted pyridyl, wherein said optional substituents are independently selected from the group consisting of hydrogen, hydroxy, halogen, cyano, alkoxy and acetoxy or combines with another of the optional substituents to form methylenedioxy or ethylenedioxy;

Y is cyano; and

Z is NR<sub>22</sub>R<sub>23</sub>, wherein R<sub>22</sub> and R<sub>23</sub> are independently H or C<sub>1-4</sub> alkyl.

26. (previously presented) The compound of claim 25, wherein said compound is selected from the group consisting of:

2-Amino-4-(5-cyano-pyridin-3-yl)-3-cyano-7-methyl-4*H*-  
pyrrolo[2,3-*h*]chromene;

2-Amino-4-(5-chloro-pyridin-3-yl)-3-cyano-7-methyl-4*H*-  
pyrrolo[2,3-*h*]chromene;

2-Amino-4-(5-chloro-6-hydroxy-pyridin-3-yl)-3-cyano-7-methyl-4*H*-  
pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(5-methyl-pyridin-3-yl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-4-(5-bromo-pyridin-3-yl)-3-cyano-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(5-methyl-pyridin-3-yl)-7-hydroxymethyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-4-(5-bromo-pyridin-3-yl)-3-cyano-7-hydroxymethyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(5-methoxy-pyridin-3-yl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene; and

4,7,10,13,16,19-Docosahexaenoic acid {2-Amino-3-cyano-4-(5-methyl-pyridin-3-yl)-4*H*-pyrrolo[2,3-*h*]chromene}-7-ylmethyl ester;  
or a pharmaceutically acceptable salt thereof.

27.-53. (cancelled).

54. (previously presented) A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

55.-56. (cancelled).

57. (original) The pharmaceutical composition of claim 54, wherein said excipient or carrier is selected from the group consisting of saccharides, starch pastes, gelatin, tragacanth, cellulose preparations, calcium phosphates and polyvinyl pyrrolidone.

58. (previously presented) The pharmaceutical composition of claim 57, wherein said excipient or carrier is a saccharide selected from the group consisting of lactose, sucrose, mannitol and sorbitol.

59. (original) The pharmaceutical composition of claim 54, wherein said excipient or carrier is a lipophilic solvent.

60. (original) The pharmaceutical composition of claim 59, wherein said lipophilic solvent is selected from the group consisting of fatty oils, fatty acid esters, polyethylene glycols and paraffin hydrocarbons.

61. (original) The pharmaceutical composition of claim 59, wherein said lipophilic solvent is selected from the group consisting of sesame oil, ethyl oleate, triglycerides, polyethylene glycol-400, cremophor and cyclodextrins.

62. (original) The pharmaceutical composition of claim 54, wherein said excipient or carrier is selected from the group consisting of vegetable oils, mineral oils, white petrolatum, branched chain fats, branched chain oils, animal fats and high molecular weight alcohol (greater than C<sub>12</sub>).

63. (original) The pharmaceutical composition of claim 54, wherein said excipient or carrier is a saline solution.

64. (previously presented) The pharmaceutical composition of claim 54, wherein said compound is selected from the group consisting of:

2-Amino-4-(5-cyano-pyridin-3-yl)-3-cyano-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-4-(5-chloro-pyridin-3-yl)-3-cyano-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-4-(5-chloro-6-hydroxy-pyridin-3-yl)-3-cyano-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(5-methyl-pyridin-3-yl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-4-(5-bromo-pyridin-3-yl)-3-cyano-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-4-(3-bromo-4,5-dimethoxyphenyl)-3-cyano-7-methyl-4*H*-imidazo[4,5-*h*]chromene;

2-Amino-4-(5-bromo-pyridin-3-yl)-3-cyano-7-methyl-4*H*-imidazo[4,5-*h*]chromene;

2-Amino-3-cyano-4-(5-methyl-pyridin-3-yl)-7-methyl-4*H*-imidazo[4,5-*h*]chromene;

2-Amino-4-(3-bromo-4,5-dimethoxyphenyl)-3-cyano-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-4-(3-bromo-4,5-dimethoxyphenyl)-3-cyano-7-hydroxymethyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-4-(3-bromo-4-hydroxy-5-methoxyphenyl)-3-cyano-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(5-methyl-pyridin-3-yl)-7-hydroxymethyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-4-(5-bromo-pyridin-3-yl)-3-cyano-7-hydroxymethyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-4-(4-acetoxy-3-bromo-5-methoxyphenyl)-3-cyano-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-4-(3-bromo-4,5-dimethoxyphenyl)-3-cyano-8,9-dihydro-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3,4,5-trimethoxyphenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3-nitrophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3,5-dimethoxyphenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3,4-methylenedioxy-5-methoxyphenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3-methoxyphenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3-bromophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3,5-difluorophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(4,5-dimethoxy-3-iodophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3-cyanophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3,4,5-trimethoxyphenyl)-7-hydroxymethyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3,5-dimethoxyphenyl)-7-hydroxymethyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3,5-difluorophenyl)-8,9-dihydro-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-4-(5-methyl-pyridin-3-yl)-3-cyano-7-methyl-8,9-dihydro-4*H*-pyrrolo[2,3-*h*]chromene;

4,7,10,13,16,19-Docosahexaenoic acid {2-Amino-4-(3-bromo-4,5-dimethoxyphenyl)-3-cyano-4*H*-pyrrolo[2,3-*h*]chromene}-7-ylmethyl ester;

4,7,10,13,16,19-Docosahexaenoic acid {2-Amino-3-cyano-4-(5-methyl-pyridin-3-yl)-4*H*-pyrrolo[2,3-*h*]chromene}-7-ylmethyl ester;

2-Amino-3-cyano-4-(3-fluorophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(4-cyanophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3-chlorophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3,5-dichlorophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3,4-dichlorophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-7,9-dimethyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3,4-difluorophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3-fluoro-4-chlorophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3-bromo-4-fluorophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene; and

2-Amino-3-cyano-4-(3-cyano-4-fluorophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene; and

2-Amino-3-cyano-4-(5-methoxy-pyridin-3-yl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;



or a pharmaceutically acceptable salt thereof.

65. (withdrawn) A method of treating a disorder responsive to the induction of apoptosis in an animal suffering therefrom, comprising administering to a mammal in need of such treatment an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

66.-67. (cancelled).

68. (withdrawn) The method of claim 65, wherein each of R<sub>3</sub>-R<sub>5</sub> is hydrogen.

69. (cancelled).

70. (cancelled).

71. (withdrawn, currently amended) The method of claim ~~70~~ 65, wherein Z is NH<sub>2</sub>.

72.-78. (cancelled).

79. (withdrawn) The method of claim 65, wherein said compound is selected from the group consisting of:

2-Amino-4-(5-cyano-pyridin-3-yl)-3-cyano-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-4-(5-chloro-pyridin-3-yl)-3-cyano-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-4-(5-chloro-6-hydroxy-pyridin-3-yl)-3-cyano-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(5-methyl-pyridin-3-yl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-4-(5-bromo-pyridin-3-yl)-3-cyano-7-methyl-4*H*-  
pyrrolo[2,3-*h*]chromene;

2-Amino-4-(3-bromo-4,5-dimethoxyphenyl)-3-cyano-7-methyl-4*H*-  
imidazo[4,5-*h*]chromene;

2-Amino-4-(5-bromo-pyridin-3-yl)-3-cyano-7-methyl-4*H*-  
imidazo[4,5-*h*]chromene;

2-Amino-3-cyano-4-(5-methyl-pyridin-3-yl)-7-methyl-4*H*-  
imidazo[4,5-*h*]chromene;

2-Amino-4-(3-bromo-4,5-dimethoxyphenyl)-3-cyano-7-methyl-4*H*-  
pyrrolo[2,3-*h*]chromene;

2-Amino-4-(3-bromo-4,5-dimethoxyphenyl)-3-cyano-7-hydroxymethyl-4*H*-  
pyrrolo[2,3-*h*]chromene;

Amino-4-(3-bromo-4-hydroxy-5-methoxyphenyl)-3-cyano-7-methyl-4*H*-  
pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(5-methyl-pyridin-3-yl)-7-hydroxymethyl-4*H*-  
pyrrolo[2,3-*h*]chromene;

2-Amino-4-(5-bromo-pyridin-3-yl)-3-cyano-7-hydroxymethyl-4*H*-  
pyrrolo[2,3-*h*]chromene;

2-Amino-4-(4-acetoxy-3-bromo-5-methoxyphenyl)-3-cyano-7-methyl-4*H*-  
pyrrolo[2,3-*h*]chromene;

2-Amino-4-(3-bromo-4,5-dimethoxyphenyl)-3-cyano-8,9-dihydro-7-methyl-4*H*-  
pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3,4,5-trimethoxyphenyl)-7-methyl-4*H*-  
pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3-nitrophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3,5-dimethoxyphenyl)-7-methyl-4*H*-  
pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3,4-methylenedioxy-5-methoxyphenyl)-7-methyl-4*H*-  
pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3-methoxyphenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3-bromophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;

2-Amino-3-cyano-4-(3,5-difluorophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;  
2-Amino-3-cyano-4-(4,5-dimethoxy-3-iodophenyl)-7-methyl-4*H*-  
pyrrolo[2,3-*h*]chromene;  
2-Amino-3-cyano-4-(3-cyanophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;  
2-Amino-3-cyano-4-(3,4,5-trimethoxyphenyl)-7-hydroxymethyl-4*H*-  
pyrrolo[2,3-*h*]chromene;  
2-Amino-3-cyano-4-(3,5-dimethoxyphenyl)-7-hydroxymethyl-4*H*-  
pyrrolo[2,3-*h*]chromene;  
2-Amino-3-cyano-4-(3,5-difluorophenyl)-8,9-dihydro-7-methyl-4*H*-  
pyrrolo[2,3-*h*]chromene;  
2-Amino-4-(5-methyl-pyridin-3-yl)-3-cyano-7-methyl-8,9-dihydro-4*H*-  
pyrrolo[2,3-*h*]chromene;  
4,7,10,13,16,19-Docosahexaenoic acid {2-Amino-4-(3-bromo-4,5-  
dimethoxyphenyl)-3-cyano-4*H*-pyrrolo[2,3-*h*]chromene}-7-ylmethyl ester;  
4,7,10,13,16,19-Docosahexaenoic acid {2-Amino-3-cyano-4-(5-methyl-pyridin-  
3-yl)-4*H*-pyrrolo[2,3-*h*]chromene}-7-ylmethyl ester;  
2-Amino-3-cyano-4-(3-fluorophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;  
2-Amino-3-cyano-4-(4-cyanophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;  
2-Amino-3-cyano-4-(3-chlorophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;  
2-Amino-3-cyano-4-(3,5-dichlorophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;  
2-Amino-3-cyano-4-(3,4-dichlorophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;  
2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-7,9-dimethyl-4*H*-  
pyrrolo[2,3-*h*]chromene;  
2-Amino-3-cyano-4-(3,4-difluorophenyl)-7-methyl-4*H*-pyrrolo[2,3-*h*]chromene;  
2-Amino-3-cyano-4-(3-fluoro-4-chlorophenyl)-7-methyl-4*H*-  
pyrrolo[2,3-*h*]chromene;  
2-Amino-3-cyano-4-(3-bromo-4-fluorophenyl)-7-methyl-4*H*-  
pyrrolo[2,3-*h*]chromene;  
2-Amino-3-cyano-4-(3-cyano-4-fluorophenyl)-7-methyl-4*H*-  
pyrrolo[2,3-*h*]chromene; and

2-Amino-3-cyano-4-(5-methoxy-pyridin-3-yl)-7-methyl-4*H*-  
pyrrolo[2,3-*h*]chromene;  
or a pharmaceutically acceptable salt thereof.

80. (withdrawn) The method of claim 65, wherein said disorder is cancer.

81. (withdrawn) The method of claim 80, wherein said cancer is selected from the group consisting of Hodgkin's disease, non-Hodgkin's lymphoma, acute and chronic lymphocytic leukemias, multiple myeloma, neuroblastoma, breast carcinoma, ovarian carcinoma, lung carcinoma, Wilms' tumor, cervical carcinoma, testicular carcinoma, soft-tissue sarcoma, chronic lymphocytic leukemia, primary macroglobulinemia, bladder carcinoma, chronic granulocytic leukemia, primary brain carcinoma, malignant melanoma, small-cell lung carcinoma, stomach carcinoma, colon carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, malignant melanoma, choriocarcinoma, mycosis fungoides, head and neck carcinoma, osteogenic sarcoma, pancreatic carcinoma, acute granulocytic leukemia, hairy cell leukemia, neuroblastoma, rhabdomyosarcoma, Kaposi's sarcoma, genitourinary carcinoma, thyroid carcinoma, esophageal carcinoma, malignant hypercalcemia, cervical hyperplasia, renal cell carcinoma, endometrial carcinoma, polycythemia vera, essential thrombocytosis, adrenal cortex carcinoma, skin cancer and prostatic carcinoma.

82. (withdrawn) The method of claim 81, wherein said cancer is a drug resistant cancer.

83. (withdrawn) The method of claim 80, additionally comprising administering at least one known cancer chemotherapeutic agent, or a pharmaceutically acceptable salt of said agent.

84. (withdrawn) The method of claim 83, wherein said known cancer therapeutic agent is selected from the group consisting of busulfan, cis-platin, mitomycin C, carboplatin, colchicine, vinblastine, paclitaxel, docetaxel, camptothecin,

topotecan, doxorubicin, etoposide, 5-azacytidine, 5-fluorouracil, methotrexate, 5-fluoro-2'-deoxy-uridine, ara-C, hydroxyurea, thioguanine, melphalan, chlorambucil, cyclophosphamide, ifosfamide, vincristine, mitoguazone, epirubicin, aclarubicin, bleomycin, mitoxantrone, elliptinium, fludarabine, octreotide, retinoic acid, tamoxifen, Herceptin<sup>®</sup>, Rituxan<sup>®</sup> and alanosine.

85. (withdrawn) The method of claim 80, additionally comprising treating with radiation-therapy.

86. (withdrawn) The method of claim 80, wherein said compound is administered after surgical treatment for cancer.

87. (withdrawn) The method of claim 65, wherein said disorder is an autoimmune disease.

88. (withdrawn) The method of claim 65, wherein said disorder is rheumatoid arthritis.

89. (withdrawn) The method of claim 65, wherein said disorder is inflammation.

90. (withdrawn) The method of claim 89, wherein said inflammation is inflammatory bowel disease.

91. (withdrawn) The method of claim 65, wherein said disorder is a skin disease.

92. (withdrawn) The method of claim 91, wherein said disorder is psoriasis.

93. (previously presented) The compound of claim 1, wherein R<sub>1</sub> is methyl.

94. (previously presented) The compound of claim 1, wherein R<sub>1</sub> is hydroxymethyl.

95. (previously presented) The composition of claim 54, wherein R<sub>1</sub> is methyl.

96. (previously presented) The composition of claim 54, wherein R<sub>1</sub> is hydroxymethyl.

97. (withdrawn) The method of claim 65, wherein R<sub>1</sub> is methyl.

98. (withdrawn) The method of claim 65, wherein R<sub>1</sub> is hydroxymethyl.

99. (previously presented) The compound of claim 1, wherein said ester of said hydroxymethyl is obtained by condensation of the hydroxymethyl group with a C<sub>1-40</sub> carboxylic acid or with a C<sub>3-6</sub> dioic acid or anhydride thereof.

100. (previously presented) The composition of claim 54, wherein said ester of said hydroxymethyl is obtained by condensation of the hydroxymethyl group with a C<sub>1-40</sub> carboxylic acid or with a C<sub>3-6</sub> dioic acid or anhydride thereof.

101. (withdrawn) The method of claim 65, wherein said ester of said hydroxymethyl is obtained by condensation of the hydroxymethyl group with a C<sub>1-40</sub> carboxylic acid or with a C<sub>3-6</sub> dioic acid or anhydride thereof.